首页> 美国卫生研究院文献>Breast Cancer Research : BCR >Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients
【2h】

Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients

机译:单独使用抗细胞角蛋白或与抗EpCAM抗体联合富集可显着提高转移性​​乳腺癌患者循环肿瘤细胞检测的敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionCirculating tumor cells (CTCs) are detectable in most cancer patients and they can meet an existing medical need to monitor cancer patients during a course of treatment and to help determine recurrent disease. CTCs are rarely found in the blood of cancer patients and enrichment is necessary for sensitive CTC detection. Most CTC enrichment technologies are anti-EpCAM antibody based even though CTC identification criteria are cytokeratin positive (CK+), CD45 negative (CD45-) and 4'6-diamidino-2-phenylindole (nuclear stain) positive (DAPI+). However, some tumor cells express low or no EpCAM. Here we present a highly sensitive and reproducible enrichment method that is based on binding to anti-CK alone or a combination of anti-CK and anti-EpCAM antibodies.
机译:简介在大多数癌症患者中都可以检测到循环肿瘤细胞(CTC),它们可以满足现有的医疗需求,以在治疗过程中监测癌症患者并帮助确定复发性疾病。在癌症患者的血液中很少发现四氯化碳,因此富集对于敏感的四氯化碳检测是必要的。即使CTC鉴定标准是细胞角蛋白阳性(CK + ),CD45阴性(CD45 -)和4'6-diamidino--,大多数CTC富集技术都是基于抗EpCAM抗体的。 2-苯基吲哚(核染色)阳性(DAPI + )。然而,一些肿瘤细胞表达低或不表达EpCAM。在这里,我们提出了一种高度敏感且可重现的富集方法,该方法基于与单独的抗CK或抗CK和抗EpCAM抗体的结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号